These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 21910571

  • 21. Pancreatic NETs: where do we stand now?
    Faivre S, Castellano D, Strosberg J, González E, Salazar R.
    Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
    [Abstract] [Full Text] [Related]

  • 22. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
    Naraev BG, Strosberg JR, Halfdanarson TR.
    Oncology; 2012 Mar; 83(3):117-27. PubMed ID: 22797357
    [Abstract] [Full Text] [Related]

  • 23. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R, Meyer T.
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [Abstract] [Full Text] [Related]

  • 24. [Recent progress in the molecular-targeting treatment of neuroendocrine tumors].
    Unno M.
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):392-5. PubMed ID: 20203442
    [No Abstract] [Full Text] [Related]

  • 25. The genetics of neuroendocrine tumors.
    Öberg K.
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [Abstract] [Full Text] [Related]

  • 26. Advances in pancreatic neuroendocrine tumor treatment.
    Castellano D, Grande E, Barriuso J.
    N Engl J Med; 2011 May 12; 364(19):1872-3; author reply 1873-4. PubMed ID: 21561356
    [No Abstract] [Full Text] [Related]

  • 27. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D, Spada F, Lambrescu I, Rubino M, Cella C, Gibelli B, Grana C, Ribero D, Bertani E, Ravizza D, Bonomo G, Funicelli L, Pisa E, Zerini D, Fazio N, IEO ENETS Center of Excellence for GEP NETs.
    Target Oncol; 2017 Oct 12; 12(5):611-622. PubMed ID: 28634872
    [Abstract] [Full Text] [Related]

  • 28. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J, Heymach JV, Zurita AJ.
    Mol Diagn Ther; 2012 Jun 01; 16(3):151-61. PubMed ID: 22515658
    [Abstract] [Full Text] [Related]

  • 29. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT.
    Clin Adv Hematol Oncol; 2014 Dec 01; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract] [Full Text] [Related]

  • 30. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
    Wang W, Jiang CY, Wang HW.
    J Clin Gastroenterol; 2015 Jan 01; 49(1):89-90. PubMed ID: 24921213
    [No Abstract] [Full Text] [Related]

  • 31. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
    Dong M, Phan AT, Yao JC.
    Clin Cancer Res; 2012 Apr 01; 18(7):1830-6. PubMed ID: 22338018
    [Abstract] [Full Text] [Related]

  • 32. Neuroendocrine tumors: treatment updates.
    Khagi S, Saif MW.
    JOP; 2013 Jul 10; 14(4):367-71. PubMed ID: 23846929
    [Abstract] [Full Text] [Related]

  • 33. New therapeutic options for metastatic malignant insulinomas.
    de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.
    Clin Endocrinol (Oxf); 2011 Sep 10; 75(3):277-84. PubMed ID: 21649688
    [Abstract] [Full Text] [Related]

  • 34. Targeted therapies: Good news for advanced-stage pancreatic neuroendocrine tumors.
    Spiegel AM, Libutti SK.
    Nat Rev Clin Oncol; 2011 May 10; 8(5):258-9. PubMed ID: 21448150
    [No Abstract] [Full Text] [Related]

  • 35. Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
    Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.
    Target Oncol; 2012 Sep 10; 7(3):173-81. PubMed ID: 22923165
    [Abstract] [Full Text] [Related]

  • 36. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
    Procopio G, Pusceddu S, Buzzoni R.
    Tumori; 2012 Sep 10; 98(3):394. PubMed ID: 22825518
    [No Abstract] [Full Text] [Related]

  • 37. Advances in pancreatic neuroendocrine tumor treatment.
    Berruti A, Pia A, Terzolo M.
    N Engl J Med; 2011 May 12; 364(19):1871-2; author reply 1873-4. PubMed ID: 21561357
    [No Abstract] [Full Text] [Related]

  • 38. Sunitinib for advanced pancreatic neuroendocrine tumors.
    Hubner RA, Valle JW.
    Expert Rev Anticancer Ther; 2011 Dec 12; 11(12):1817-27. PubMed ID: 22117148
    [Abstract] [Full Text] [Related]

  • 39. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A, Kamp K, Kaltsatou M, O'Toole D, Kaltsas G, de Herder W.
    Neuroendocrinology; 2017 Dec 12; 105(4):394-402. PubMed ID: 28122378
    [Abstract] [Full Text] [Related]

  • 40. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Eriksson B.
    Curr Opin Oncol; 2010 Jul 12; 22(4):381-6. PubMed ID: 20473165
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.